Annexin A1, calreticulin and high mobility group box 1 are elevated in secondary progressive multiple sclerosis: Does immunogenic cell death occur in multiple sclerosis?

IF 2.2 4区工程技术 Q3 PHARMACOLOGY & PHARMACY

Bioimpacts Pub Date : 2024-09-08 eCollection Date: 2025-01-01 DOI:10.34172/bi.30264

Mohammad Saeid Hejazi, Sevda Jafari, Soheila Montazersaheb, Ommoleila Molavi, Vahid Hosseini, Mahnaz Talebi, Masoud Nikanfar

{"title":"Annexin A1, calreticulin and high mobility group box 1 are elevated in secondary progressive multiple sclerosis: Does immunogenic cell death occur in multiple sclerosis?","authors":"Mohammad Saeid Hejazi, Sevda Jafari, Soheila Montazersaheb, Ommoleila Molavi, Vahid Hosseini, Mahnaz Talebi, Masoud Nikanfar","doi":"10.34172/bi.30264","DOIUrl":null,"url":null,"abstract":"Introduction: Multiple sclerosis (MS) is a chronic neuroinflammatory diseases characterized by demyelination of the nerve fibers. Immunogenic cell death (ICD) is a process, during which damaged and stressed cells release danger-associated molecular patterns (DAMPs) activating immune responses. This study aimed to elucidate the induction of ICD in MS diseases.Methods: To achieve this goal, the level of DAMPs including Annexin A1 (ANXA1), calreticulin and HMGB1 was measured in the cerebrospinal fluid (CSF) of a secondary progressive multiple sclerosis (SPMS) patient in comparison to control group.Results: Results showed significant upregulation (more than two-fold) of ANXA1, calreticulin (CRT) and HMGB1 in the CSF of the patient.Conclusion: Although further studies are suggested in this regard, this data could imply induction of ICD in MS. The proposed ICD might trigger immune response against neural cells resulting in neuroinflammation and demyelination in CNS in MS. Our observation could suggest inclusion of ICD interfering treatments in routine MS therapy.","PeriodicalId":48614,"journal":{"name":"Bioimpacts","volume":"15 ","pages":"30264"},"PeriodicalIF":2.2000,"publicationDate":"2024-09-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11954741/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Bioimpacts","FirstCategoryId":"5","ListUrlMain":"https://doi.org/10.34172/bi.30264","RegionNum":4,"RegionCategory":"工程技术","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/1/1 0:00:00","PubModel":"eCollection","JCR":"Q3","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}

引用次数: 0

Abstract

Introduction: Multiple sclerosis (MS) is a chronic neuroinflammatory diseases characterized by demyelination of the nerve fibers. Immunogenic cell death (ICD) is a process, during which damaged and stressed cells release danger-associated molecular patterns (DAMPs) activating immune responses. This study aimed to elucidate the induction of ICD in MS diseases.

Methods: To achieve this goal, the level of DAMPs including Annexin A1 (ANXA1), calreticulin and HMGB1 was measured in the cerebrospinal fluid (CSF) of a secondary progressive multiple sclerosis (SPMS) patient in comparison to control group.

Results: Results showed significant upregulation (more than two-fold) of ANXA1, calreticulin (CRT) and HMGB1 in the CSF of the patient.

Conclusion: Although further studies are suggested in this regard, this data could imply induction of ICD in MS. The proposed ICD might trigger immune response against neural cells resulting in neuroinflammation and demyelination in CNS in MS. Our observation could suggest inclusion of ICD interfering treatments in routine MS therapy.

查看原文本刊更多论文

导言多发性硬化症（MS）是一种以神经纤维脱髓鞘为特征的慢性神经炎症性疾病。免疫性细胞死亡（ICD）是受损和受压细胞释放危险相关分子模式（DAMPs）激活免疫反应的过程。本研究旨在阐明多发性硬化症疾病中诱导 ICD 的原因：为了实现这一目标，研究人员测量了继发性进行性多发性硬化症（SPMS）患者脑脊液（CSF）中的 DAMPs 水平，包括附件蛋白 A1 (ANXA1)、钙粘蛋白和 HMGB1，并与对照组进行了比较：结果显示，患者脑脊液中的ANXA1、钙网蛋白（CRT）和HMGB1明显上调（超过两倍）：尽管在这方面还需要进一步研究，但这些数据可能意味着多发性硬化症中存在ICD诱导。所提出的 ICD 可能会引发针对神经细胞的免疫反应，从而导致多发性硬化症患者中枢神经系统的神经炎症和脱髓鞘。我们的观察结果表明，在多发性硬化症的常规治疗中应纳入干扰 ICD 的治疗方法。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Bioimpacts Pharmacology, Toxicology and Pharmaceutics-Pharmaceutical Science

CiteScore

4.80

自引率

7.70%

发文量

审稿时长

5 weeks

期刊介绍： BioImpacts (BI) is a peer-reviewed multidisciplinary international journal, covering original research articles, reviews, commentaries, hypotheses, methodologies, and visions/reflections dealing with all aspects of biological and biomedical researches at molecular, cellular, functional and translational dimensions.